Treatment cost of pancreatic cancer in Japan: Analysis of the difference after the introduction of gemcitabine

Japanese Journal of Clinical Oncology

Volumn 35, Issue 9, 2005, Pages 526-530

  Ishii, Hiroshi ^a   Furuse, Junji ^a   Kinoshita, Taira ^a   Konishi, Masaru ^a   Nakagohri, Toshio ^a   Takahashi, Shinichiro ^a   Gotohda, Naoto ^a   Nakachi, Kouhei ^a   Suzuki, Ei Ichiro ^a   Yoshino, Masahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Chemotherapy; Cost analysis; Investigational new drug application; Pancreatic neoplasm; Treatment cost

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS CANCER; PANCREAS RESECTION; SURVIVAL TIME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DRUG COSTS; FEMALE; FLUOROURACIL; HUMANS; JAPAN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 27644556152     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi144     Document Type: Article

References (13)

1. The Editorial Board of the Cancer Statistics in Japan. Cancer Statistics in Japan 2003. Tokyo: Foundation for promotion of cancer research.
2. Okada S, Yoshimori M, Kakizoe T. Pancreatic cancer: Medical aspects. Pancreas 1998;16:349-54.
3. Okada S. Non-surgical treatment of pancreatic cancer. Int J Clin Oncol 1999;4:257-66.
4. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-53.
5. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-13.
6. Okada S, Ueno H, Okusaka T, Ikeda M, Furuse J, Maru Y. Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2001;31:7-12.
7. Ishii H, Furuse J, Nagase M, Yoshino M. Impact of gemcitabine on the treatment of advanced pancreatic cancer. J Gastroenterol Hepatol 2005;20:62-6.
8. Ministry of Health, Labour and Welfare. Statistical Information. Outline of Estimates of National Medical Care Expenditure at 1999. Available at http://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/99/kekkal.html.
9. Furuse J, Kinoshita T, Kawashima M, Ishii H, Nagase M, Konishi M, et al. Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma. Cancer 2003;97:1346-52.
10. Junji Furuse, Hiroshi Ishii, Mitsuhiko Kawashima, Michitaka Nagase, Keiji Nihei, Kohei Nakachi, et al. A phase I study of hypofractionated radiotherapy followed by systemic chemotherapy with full-dose gemcitabine in patients with unresectable locally advanced pancreatic cancer. Hepatogastroenterol (in press).
11. Ishii H, Furuse J, Nagase M, Yoshino M, Kawashima M, Satake M, et al. Hepatic arterial infusion of 5-fluorouracil and extra-beam radiotherapy for liver metastases from pancreatic carcinoma. Hepatogastroenterol 2004;51:1175-8.
12. Hjelmgren J, Ceberg J, Persson U, Alvegard TA. The cost of treating pancreatic cancer - a cohort study based on patients' records from four hospitals in Sweden. Acta Oncol 2003;42:218-26.
13. Du W, Touchette D, Vaitkevicius VK, Peters WP, Shields AF. Cost analysis of pancreatic carcinoma treatment. Cancer 2000;89:1917-24.